---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-258063"
form_type: "8-K"
ticker: "NTLA"
cik: "0001652130"
company_name: "Intellia Therapeutics, Inc."
filed_at: "2023-10-18T23:59:59+00:00"
generated_at: "2026-06-09T21:51:39.167928+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# FDA clears Intellia's IND for NTLA-2001 Phase 3 trial in ATTR cardiomyopathy

## Summary
- First-ever in vivo CRISPR candidate to enter late-stage clinical development (Phase 3).
- Global Phase 3 study expected to initiate by year-end 2023.
- NTLA-2001 is a single-dose, systemically administered CRISPR therapy targeting TTR gene.
- Intellia collaborates with Regeneron on development and commercialization.

## SEC filing metadata
- accession: 0001193125-23-258063
- form_type: 8-K
- ticker: NTLA
- cik: 0001652130
- company_name: Intellia Therapeutics, Inc.
- filed_at: 2023-10-18T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1652130/000119312523258063/0001193125-23-258063-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1652130/000119312523258063/d570255d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-258063
- JSON: https://secwatch.observer/filing/0001193125-23-258063.json
- Plain text: https://secwatch.observer/filing/0001193125-23-258063.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.